Susquehanna International Group
TBPH icon

Susquehanna International Group’s Theravance Biopharma TBPH Stock Holding History

Susquehanna International Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Sell
12,300
-67,000
-84% -$1.19M ﹤0.01% 11712
2025
Q4 		$1.48M Buy
79,300
+65,000
+455% +$1.08M ﹤0.01% 6285
2025
Q3 		$209K Buy
+14,300
New +$181K ﹤0.01% 10903
2024
Q1 		– Sell
-66,000
Closed -$742K – 13303
2023
Q4 		$742K Sell
66,000
-19,600
-23% -$197K ﹤0.01% 7721
2023
Q3 		$739K Buy
85,600
+69,100
+419% +$667K ﹤0.01% 7321
2023
Q2 		$171K Sell
16,500
-115,200
-87% -$1.27M ﹤0.01% 10440
2023
Q1 		$1.43M Sell
131,700
-92,000
-41% -$973K ﹤0.01% 5915
2022
Q4 		$2.51M Buy
223,700
+124,700
+126% +$1.31M ﹤0.01% 4314
2022
Q3 		$1M Buy
99,000
+10,900
+12% +$102K ﹤0.01% 6627
2022
Q2 		$798K Buy
88,100
+24,000
+37% +$221K ﹤0.01% 7077
2022
Q1 		$613K Buy
64,100
+51,900
+425% +$509K ﹤0.01% 8425
2021
Q4 		$135K Sell
12,200
-192,200
-94% -$1.68M ﹤0.01% 11909
2021
Q3 		$1.51M Buy
204,400
+152,000
+290% +$1.7M ﹤0.01% 6454
2021
Q2 		$761K Buy
52,400
+9,800
+23% +$184K ﹤0.01% 8522
2021
Q1 		$869K Buy
+42,600
New +$810K ﹤0.01% 8094
2020
Q4 		– Sell
-26,400
Closed -$390K – 11719
2020
Q3 		$390K Buy
+26,400
New +$495K ﹤0.01% 8196
2020
Q2 		– Sell
-40,700
Closed -$941K – 10908
2020
Q1 		$941K Buy
+40,700
New +$1.02M ﹤0.01% 5550
2019
Q3 		– Sell
-21,100
Closed -$345K – 10834
2019
Q2 		$345K Buy
21,100
+11,400
+118% +$231K ﹤0.01% 8047
2019
Q1 		$220K Buy
9,700
+200
+2% +$5.07K ﹤0.01% 7740
2018
Q4 		$243K Sell
9,500
-2,000
-17% -$54K ﹤0.01% 7394
2018
Q3 		$376K Buy
+11,500
New +$313K ﹤0.01% 7037
2017
Q2 		– Sell
-19,700
Closed -$725K – 9824
2017
Q1 		$725K Sell
19,700
-11,500
-37% -$367K ﹤0.01% 5796
2016
Q4 		$995K Buy
+31,200
New +$968K ﹤0.01% 5550

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's TBPH Position: Q1 2026 in Review

Susquehanna International Group increased its Theravance Biopharma (TBPH) stake by 1,460% in Q1 2026, buying an estimated $5.66M and bringing the position to 341,579 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4058.

Susquehanna International Group first reported a position in TBPH in Q2 2014 and has held it in 32 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Susquehanna International Group held 341,579 shares of Theravance Biopharma worth $5.54M as of Q1 2026.
  • Susquehanna International Group bought 319,683 Theravance Biopharma shares in Q1 2026, an estimated $5.66M.
  • Theravance Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4058 holding.
  • Susquehanna International Group first reported a position in Theravance Biopharma in Q2 2014 and has held it in 32 quarters since.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.